BackgroundTo determine the phytochemical constituents, antioxidant, and anticancer activities of Leea indica leaf extracts on DU-145 and PC-3 human prostate cancer cell lines.MethodsLeaf sample was subjected to Soxhlet extraction method with increasing polarity of solvents, namely, chloroform, ethyl acetate, methanol, ethanol, and aqueous. Phytochemical screening was done using different biochemical tests. Quantitative analysis for phenol was determined by Folin–Ciocalteu reagent method. The antioxidant activity was tested using 2,2-diphenyl-1-picrylhydrazyl, ferric ion reducing power assay, and phosphomolybdenum assay. In vitro anticancer activity on DU-145 and PC-3 human prostate cancer cell lines was evaluated by (3-(4, 5-dimethyl thiazole-2yl)-2, 5-diphenyl tetrazolium bromide) MTT assay.ResultsPhytochemical screening confirmed the presence of phyto-constituents like alkaloids, flavonoids, glycosides, phenols, lignins, saponins, sterols, tannins, anthraquinone, and reducing sugar. Methanol and ethanol extracts exhibited higher phenolic content as compare to aqueous extract. Antioxidant capacities were shown highest in methanol and ethanol extracts based on the test performed. The methanol and ethanol leaf extracts were found to be selectively cytotoxic in vitro to (DU-145 and PC-3) prostate cancer cell lines with IC50 values 529.44 ± 42.07 μg/mL and 677.11 ± 37.01 μg/mL for DU-145 and 547.55 ± 33.52 μg/mL and 631.99 ± 50.24 μg/mL for PC-3 respectively, while it had no cytotoxic effect on normal mice embryo fibroblast cells.ConclusionThe results indicate that Leea indica was a promising antioxidant and anticancer agent for DU-145 and PC-3 human prostate cancer cell lines. However, further studies are needed to conclude its therapeutic use.

Objective: Screening of preliminary phytochemicals, evaluation of in vitro antioxidant and in vitro anticancer activities of Simarouba glauca leaf extracts on T-24 Bladder cancer cell line. Materials and Methods: Herbal extraction was carried out by Soxhlet method using chloroform, ethylacetate, methanol, ethanol, aqueous and hydroalcohol. Phytochemical investigation was done using biochemical tests. Total phenolic content was estimated by Folin-Ciocalteu reagent (FCR) method. Antioxidant potential of leaf extracts was analyzed by Ferric ion reducing antioxidant power (FRAP) assay, Phosphomolybdenum (PM) assay and 2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay. In vitro anticancer activity on T-24 bladder cancer cell line was assessed by MTT assay. Statistical analysis used: Statistical analysis of data was performed by analysis of variance (one-way ANOVA) and level of statistical significance between groups was carried out using GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, CA, USA). Results: Phytochemical analysis revealed the presence of rich secondary metabolite present in all the solvent extracts. Hydroalcoholic extract showed highest presence of phenolic content (92.38±0.29 mg/g) GAE. Ethanol and methanol extract showed highest antioxidant capacity in DPPH, FRAP and PM assay as compared to the other extracts based on the test performed. The results confirmed that ethanol extract significantly (p<0.05) inhibited T-24 cell line with IC 50 value (533.55±25.02 µg/mL) as compared to standard drug doxorubicin (0.16µM/mL). Conclusions: The results of the present findings strengthen the potential property of Simarouba glauca as a resource for the discovery of novel antioxidant and anticancer agents.Key words: Antioxidant, Anticancer, Bladder Cancer, Phytochemical, Simarouba glauca. Key Messages: The use of medicinal plants have been practiced to treat cancer aliments across the world. Our study demonstrates the implication of herbal extracts to inhibit cancer cell lines at in vitro levels. However, the further approaches at in vivo level using lead compounds will give core insights of S. glauca extracts on Bladder cancer.

The UK National Health Service has now specified a maximum interval of two weeks between general practitioner (GP) referral and specialist assessment for patients with suspected cancer. We examined progress through the cancer pathway in 160 patients with potentially curable cancers of the prostate, bladder, kidney and testis before implementation of this rule. Median intervals with interquartile ranges were quantified from the first GP consultation to hospital referral, then to the first hospital consultation, confirmation of diagnosis and definitive surgery. 34% of patients were seen at the hospital within two weeks of referral. The overall median interval from GP consultation to radical surgery was 137 days, the longest being for prostate cancer (median 244). For prostate, bladder and renal cancers the principal element of delay was from the time of diagnosis to surgery (76, 73 and 26 days respectively). These results indicate that, under the two-weeks-wait rule, 2 out of every 3 patients achieve earlier initial assessment. However, the overall delay will not be substantially reduced without concomitant increases in diagnostic facilities, theatre time and human resources.

No abstract

With the flourishing of innovation in drug discovery into a new era of personalized therapy, the use of monoclonal antibodies (mAbs) in the treatment of various ailments lies at the forefront. Major improvements in genetic sequencing and biomedical techniques as well as research into mAbs emphasize on determining new targets for advanced therapy while maximizing efficacy for clinical application. However, a balance has to be achieved concerning developing a target with low toxicity combined with high specificity and versatility, to allow a specific antibody to facilitate several biotic effects, ranging from neutralization of virus mechanisms to modulation of immune response and maintaining low global economic cost. Presently, there are approximately 30 mAbs' permitted for therapeutic use with many more being tested in clinical trials. Nevertheless, the heavy cost of mAbs' production, stowage and management as well as the subsequent hindrances to their development are outweighed by mAbs' clinical advantages. Compared to conventional drugs, since mAbs use as pharmacologic iotas have specific physical features and modes of action, they should be considered as a discrete therapeutic category. In this review, the history of mAb generation and the innovative technological applications of mAbs that has advanced in clinical practices is reviewed.